<DOC>
	<DOCNO>NCT01064284</DOCNO>
	<brief_summary>The primary objective study assess immunogenicity VWF/FVIII rFVIII concentrate determine frequency inhibitor development previously untreated patient ( PUPs ) minimally blood component-treated ( MBCTPs ) first 50 EDs first 3 year enrollment , whichever occur first .</brief_summary>
	<brief_title>Survey Inhibitors Plasma-Product Exposed Toddlers</brief_title>
	<detailed_description>Patients meet enrollment criterion consecutively enrol participate centre , randomize treat exclusively single FVIII product either plasma-derived recombinant , follow inhibitor development 50 exposure day ( EDs ) 3 year enrolment elapse , whichever come first . Study product , belong class rFVIII concentrate class plasma-derived VWF/FVIII concentrate , provide free patient duration study</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject Any ethnicity Age &lt; 6 year Severe haemophilia A ( FVIII : C &lt; 1 % ) , confirm enrolment central laboratory . Those patient diagnose locally severe subsequently find FVIII level &gt; = 1 % test central laboratory separately record screening list . Previously untreated ( 0 EDs FVIII concentrate blood product ) minimally treat ( &lt; 5 EDs ) blood component , namely whole blood , fresh frozen plasma , pack red blood cell , platelet cryoprecipitate . Patients meet criterion separately record screening list . Negative inhibitor measurement local central laboratory screen Ability comply study requirement Signed informed consent legal tutor Patients accept enter study randomize separately record . Previous history FVIII inhibitor Other congenital acquire bleed defect Plasma FVIII level &gt; = 1 % , assayed central laboratory Those patient originally diagnose locally severe subsequently find FVIII level range 1 % 2 % test central laboratory separately record screening list . Concomitant congenital acquire immunodeficiency Concomitant treatment systemic immunosuppressive drug Concomitant treatment investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII inhibitor</keyword>
	<keyword>vWF/FVIII</keyword>
	<keyword>rFVIII</keyword>
</DOC>